Restricted accessResearch articleFirst published online 1982-7
Effects of Charcoal Hemoperfusion with Prostacyclin on the Coagulation-fibrinolysis System and Platelets of Patients with Fulminant Hepatic Failure — Preliminary Observations
The coagulation-fibrinolysis system and platelet function were studied in two patients with fulminant hepatic failure undergoing charcoal hemoperfusion with prostacyclin (PGI2) infusion. There was no adverse effect on the purely coagulative side and significant decreases were found only in Factors V and VII. There was a significant increase in platelet count and initially high BTG values decreased to normal. The findings suggest that PGI2 greatly improves the biocompatibility of hemoperfusion devices.
BrecherB., CronkiteE.P.: Morphology and enumeration of human blood platelets.J. Appl. Physiol., 3, 365, 1950.
2.
ChangT.M.S.: Hemoperfusion over microincapsulated charcoal adsorbent in a patient with hepatic coma.Lancet, 2, 1371, 1972.
3.
ClaussA.: Gerinnungphysilogische schnellmethode zur Bestinnung des Fibrinogens.Acta Hemat., 17, 237, 1957.
4.
EgebergO.: Assay of antihemophilic A, B and C Factor by one-stage cephalin system.Scand. J. Lab. Invest., 13, 140, 1961.
5.
FluteP.T.: Clotting abnormalities in liver disease. In: Progress in Liver Disease. Eds. PopperH., and SchaffnerF.Grune & Stratton Inc., New York, Vol. VI, p. 301, 1979.
6.
FribergerP., KnösM.: Plasminogen determination in human plasma. In: Chromogenic peptide substrates chemistry and clinical usage. Eds. ScullyM.F., and KakkarV.V.Churchill Livingstone, Edinburgh, London and New York, p. 128, 1979.
7.
GazzardB.G., WestonM.J., Murray-LyonI.M., RecordC.O., WilliamsR.: Experience at King's College Hospital with charcoal hemoperfusion: overall results in 37 patients. In: Artificial liver support. Eds. WilliamsR., and Murray-LyonI.M., Pitman Medical, London, p. 234, 1975.
8.
GiddingJ.C.: Hereditary coagulation disorders: laboratory techniques. In: Blood coagulation and hemostasis. A practical guide. Ed. ThomsonJ.M., Churchill Livingstone, Edinburgh, p. 117, 1980.
9.
GimsonA.E.S., LangleyP.G., HughesR.D., CanaleseJ., MellonP.J., WilliamsR., WoodsH.F., WestonM.J.: Prostacyclin to prevent platelet activation during charcoal hemoperfusion in fulminant hepatic failure.Lancet, 1, 173, 1980.
10.
GimsonA.E.S., CanaleseJ., HughesR.D., WilliamsR.: Developments in liver support for acute liver failure. In: Atti del Convegno <Attualità e prospettive della terapia intensiva epatologica>. Eds. BoncinelliS., Parretti Grafiche, Firenze, p. 157, 1981a.
11.
GimsonA.E.S., CanaleseJ., LangleyP.G., HughesR.D., WillliamsR.: Charcoal hemoperfusion with PGI2 in the treatment of fulminant hepatic failure. In: Artificial liver support. Eds. BrunnerG., and SchmidtF.W., Springer-Verlag, Berlin, Heidelberg and New York, p. 115, 1981b.
12.
IngramG.I.C.: Blood coagulation Factor VIII: genetics, physiological control and bioassay.Adv. in Clin. Chemistry, 21, 189, 1965.
13.
LangleyP.G., HughesR.D., TonH.Y., SilkD.B.A., WilliamsR.: The use of PGI2 in the prevention of adverse platelet reactions during charcoal hemoperfusion.Int. J. Artif. Organs, 2, 207, 1979.
14.
LaurellC.B.: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.Analytical Biochemistry, 15, 1966.
15.
LudlamC.A., MooreS., BoltonA.E., PepperD.S., CashJ.D.: The release of a human platelet specific protein measured by a radio-immuno assay.Thromb. Res., 6, 543, 1975.
16.
ØdegardO.R., AbilgaardU.: Determination of antit-hrombin III and antifactor Xa activity. In: New methods for the Analysis of Coagulation using Chromogenic Substrates. Ed. WittI., de Gruyter, Berlin and New York, p. 123, 1977.
17.
SilkD.B.A., WilliamsR.: Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal hemoperfusion and polyacrylonitrile hemodialysis.Int. J. Artif. Organs, 1, 29, 1978.
18.
TeienA.N., LieM., AbilgaardU.: Assay of heparin in plasma using a chromogenic substrate.Thromb. Res., 8, 413, 1976.
19.
TurneyJ.H., FewellM.R., WilliamsL.C., ParsonV., WestonM.J.: Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy.Lancet, 2, 219, 1980.
20.
WestonM.J., LangleyP.G., RubinM.H., HanidM.A., MellonP.J., WilliamsR.: Platelet function in fulminant hepatic failure and effect of charcoal hemoperfusion.Gut, 18, 897, 1977.
21.
WestonM.J., WoodsH.F., BuntingS., MoncadaS., VaneJ.R.: Prostacyclin eliminates the bioincompatibility of charcoal hemoperfusion.Europ. Dial. Transplant. Assoc, 16, 225, 1979.
22.
WoodsH.F., AshG., WestonM.J., BuntingS., MoncadaS., VaneJ.R.: Prostacyclin can replace heparin in hemodialysis in dogs.Lancet, 2, 1075, 1978.
23.
ZuckerM.B.: Heparin and platelet function.Fed. Proa, 36, 47, 1977.
